Health·November 10, 2026·1 min read

FDA adds vision-loss warning to popular GLP-1 drugs

Mounjaro, Ozempic, Wegovy and Zepbound among medications affected

Logo of the U.S. Food and Drug Administration (FDA).
File photoLogo of the U.S. Food and Drug Administration (FDA).U.S. Food and Drug Administration

The U.S. Food and Drug Administration is requiring new warnings on popular GLP-1 medications, including Mounjaro, Ozempic, Wegovy and Zepbound, about a rare condition that can cause sudden and potentially permanent vision loss.

The condition, non-arteritic anterior ischemic optic neuropathy (NAION), occurs when blood flow to part of the optic nerve is reduced, damaging the nerve that carries visual information from the eye to the brain. People who develop NAION typically experience a sudden, painless decrease in vision in one eye. Symptoms can include blurry or hazy areas, blind spots, loss of part of the visual field or changes in color perception. Vision lost because of NAION may be permanent.

The FDA reviewed clinical trials, observational studies and post-market safety reports involving GLP-1 drugs. In a pooled analysis of 126 clinical trials, the agency found approximately 6.4 NAION cases per 100,000 person-years among people receiving GLP-1 medications, compared with 3.8 cases per 100,000 person-years in comparison groups. The agency characterized NAION as rare and said the available evidence indicates a potential increased risk associated with the drug class.

The labeling change affects GLP-1 medications used for diabetes and weight management, including products containing semaglutide, such as Ozempic and Wegovy, and tirzepatide, the active ingredient in Mounjaro and Zepbound. The warning does not mean everyone taking these medications faces the same individual risk, and the FDA is not advising patients to routinely stop treatment because of the labeling change.

Patients are instead being advised to watch for sudden vision changes and contact a healthcare professional immediately if they experience symptoms such as sudden painless vision loss, new blind spots or significant changes in their visual field.

Community discussion
"With millions of people using GLP-1 medications, how should patients and doctors weigh a very rare but potentially permanent side effect against the benefits of treatment?"